Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

DBVT

DBV Technologies ADR

Dec 13 • 04:00PM ET

3.57

Dollar change -0.27
Percentage change -7.03	%

Healthcare • Biotechnology • France • NASD

Peers: ALNY VRNA RARE EHAB ADMA XOMA ARRY AXSM ANAB ASND

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.31	Insider Own	0.35%	Shs Outstand	20.51M	Perf Week	-2.46%
Market Cap	73.22M	Forward P/E	-	EPS next Y	-4.56	Insider Trans	-6.56%	Shs Float	20.44M	Perf Month	15.16%
Income	-102.09M	PEG	-	EPS next Q	-1.11	Inst Own	13.82%	Short Float	1.23%	Perf Quarter	-4.80%
Sales	0.00M	P/S	-	EPS this Y	33.44%	Inst Trans	-	Short Ratio	1.05	Perf Half Y	-28.42%
Book/sh	2.81	P/B	1.27	EPS next Y	9.90%	ROA	-72.19%	Short Interest	0.25M	Perf Year	-55.38%
Cash/sh	2.26	P/C	1.58	EPS next 5Y	21.22%	ROE	-103.11%	52W Range	2.20 - 10.70	Perf YTD	-62.53%
Dividend Est.	-	P/FCF	-	EPS past 5Y	35.36%	ROI	-167.16%	52W High	-66.64%	Beta	0.60
Dividend TTM	-	Quick Ratio	2.22	Sales past 5Y	0.00%	Gross Margin	-	52W Low	61.94%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	2.22	EPS Y/Y TTM	0.58%	Oper. Margin	-	RSI (14)	52.08	Volatility	7.86% 11.78%
Employees	104	Debt/Eq	0.28	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.50	Target Price	19.66
Option/Short	No / No	LT Debt/Eq	0.13	EPS Q/Q	-81.65%	Payout	-	Rel Volume	1.05	Prev Close	3.84
Sales Surprise	-3.21%	EPS Surprise	11.11%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	240.46K	Price	3.57
SMA20	9.75%	SMA50	3.04%	SMA200	-28.84%	Trades		Volume	253,123	Change	-7.03%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-04-23	Upgrade	Societe Generale	Hold → Buy
Dec-16-22	Downgrade	Goldman	Neutral → Sell
May-10-22	Downgrade	Goldman	Buy → Neutral	$6 → $1.50
Sep-14-21	Upgrade	Societe Generale	Hold → Buy
Jan-22-21	Downgrade	Societe Generale	Hold → Sell
Nov-02-20	Upgrade	Societe Generale	Sell → Hold
Aug-06-20	Downgrade	Societe Generale	Buy → Sell
Aug-05-20	Reiterated	H.C. Wainwright	Buy	$25 → $14
Mar-17-20	Downgrade	Stifel	Buy → Hold	$18 → $6
Jan-09-20	Upgrade	Stifel	Hold → Buy	$10 → $18
Dec-16-19	Initiated	Citigroup	Buy
Sep-05-19	Resumed	Morgan Stanley	Equal-Weight
Jun-17-19	Initiated	Goldman	Buy
Dec-20-18	Downgrade	Stifel	Buy → Hold
Dec-20-18	Downgrade	Jefferies	Buy → Hold
Dec-20-18	Downgrade	BofA/Merrill	Buy → Underperform
Dec-20-18	Downgrade	Barclays	Overweight → Equal Weight
Oct-31-17	Upgrade	Societe Generale	Sell → Hold
Oct-24-17	Downgrade	Societe Generale	Buy → Sell
Oct-23-17	Downgrade	Morgan Stanley	Overweight → Equal-Weight

Show Previous Ratings

Dec-12-24 09:59AM	DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids (Benzinga) +16.72%
Dec-11-24 04:05PM	DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin Peanut Patch in Toddlers 1 3 Years-Old (GlobeNewswire)
Dec-02-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 (GlobeNewswire) +7.05%
Nov-11-24 04:30PM	DBV Technologies Announces Plan to Implement ADS Ratio Change (GlobeNewswire) -6.07%
Nov-06-24 04:30PM	DBV Technologies Reports Third Quarter 2024 Financial Results (GlobeNewswire)
08:31AM	Loading…
Oct-24-24 08:31AM	DBV Technologies price target raised to $7 from $5 at H.C. Wainwright (TipRanks) +23.14%
Oct-22-24 04:45PM	DBV Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe (GlobeNewswire)
Oct-18-24 04:30PM	DBV Technologies to Participate in Upcoming ACAAI 2024 Congress (GlobeNewswire)
Oct-14-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (GlobeNewswire)
Sep-23-24 04:30PM	DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial (GlobeNewswire) -6.03%
Sep-04-24 04:30PM	DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.63%
Aug-02-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (GlobeNewswire)
Jul-30-24 08:55PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:30PM	DBV Technologies Announces Filing of 2024 Half-Year Report ? Conditions for Accessing or Consulting the Report (GlobeNewswire)
04:30PM	DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results (GlobeNewswire)
01:30AM	Loading…
Jul-29-24 01:30AM	DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 (GlobeNewswire)
Jul-08-24 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jun-05-24 04:30PM	DBV Technologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-24 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2024 (GlobeNewswire)
May-31-24 09:51AM	DBV Technologies Announces Plan to Implement ADS Ratio Change (GlobeNewswire)
May-30-24 04:30PM	DBV Technologies to Participate in Upcoming EAACI 2024 Congress (GlobeNewswire)
May-17-24 04:30PM	DBV Technologies Announces Plan to Implement ADS Ratio Change (GlobeNewswire) +7.97%
May-16-24 04:30PM	DBV Technologies Announces Results of its 2024 Combined General Meeting (GlobeNewswire)
May-09-24 04:30PM	DBV Technologies to Participate in Upcoming Investor Conferences (GlobeNewswire) -17.77%
May-07-24 11:53PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:30PM	DBV Technologies Reports First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Apr-25-24 04:30PM	Combined General Meeting of May 16, 2024 (GlobeNewswire)
Apr-04-24 04:43PM	Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (GlobeNewswire) -6.67% +10.00%
Mar-08-24 11:01AM	DBV Technologies S.A. (NASDAQ:DBVT) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:33AM	DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document (GlobeNewswire)
10:52PM	Loading…
Mar-07-24 10:52PM	DBVT Stock Earnings: DBV Technologies Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:30PM	DBV Technologies Reports Full Year 2023 Financial Results and Business Update (GlobeNewswire)
Mar-04-24 04:30PM	DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 (GlobeNewswire)
Feb-20-24 04:30PM	DBV Technologies to Participate in Upcoming AAAAI 2024 Congress (GlobeNewswire) -7.58%
Jan-16-24 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Dec-04-23 04:30PM	Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (GlobeNewswire) -5.79% +6.21%
Nov-09-23 04:30PM	DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin Peanut in Toddlers (GlobeNewswire) -5.66%
Nov-06-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (GlobeNewswire)
Nov-02-23 04:30PM	DBV Technologies to Present New Data at ACAAI 2023 (GlobeNewswire)
Oct-31-23 04:30PM	DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-27-23 04:30PM	DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Oct-16-23 02:00AM	DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer (GlobeNewswire)
Oct-05-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023 (GlobeNewswire)
Sep-05-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire) +11.46% -5.71%
Jul-31-23 04:25PM	DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results (GlobeNewswire) -6.33% +8.78%
Jul-25-23 04:30PM	DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update (GlobeNewswire)
Jul-19-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023 (GlobeNewswire)
Jul-10-23 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jun-16-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023 (GlobeNewswire)
Jun-08-23 04:30PM	DBV Technologies to Participate in Upcoming EAACI Congress 2023 (GlobeNewswire)
Jun-06-23 05:00PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
May-10-23 05:30PM	DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin Peanut in Toddlers (GlobeNewswire) +12.12%
May-09-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
May-04-23 04:30PM	DBV Technologies Reports First Quarter 2023 Financial Results (GlobeNewswire) +5.77%
Apr-19-23 05:09PM	DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 3 Years After Receiving Pre-BLA Responses from FDA (GlobeNewswire)
Apr-12-23 04:30PM	DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting (GlobeNewswire)
Mar-24-23 04:30PM	Ordinary and Extraordinary General Meeting of April 12, 2023 (GlobeNewswire)
Mar-13-23 01:30AM	DBV Technologies Update (GlobeNewswire)
Mar-07-23 04:30PM	DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 7 Years Old (GlobeNewswire) +14.57%
Mar-02-23 05:30PM	DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document (GlobeNewswire) -5.52% +5.11%
04:30PM	DBV Technologies Reports Full Year 2022 Financial Results and Business Update (GlobeNewswire)
Feb-27-23 01:30AM	DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023 (GlobeNewswire)
Feb-21-23 04:30PM	DBV Technologies to Participate in Upcoming AAAAI 2023 Congress (GlobeNewswire)
Feb-10-23 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire)
Jan-23-23 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire)
Jan-04-23 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of December 31, 2022 (GlobeNewswire)
Dec-23-22 01:30AM	DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial (GlobeNewswire) +22.03%
Dec-08-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2022 (GlobeNewswire)
Nov-22-22 04:30PM	DBV Technologies to Participate in Upcoming Investor Conference (GlobeNewswire) +5.34%
Nov-09-22 01:30AM	DBV Technologies to Highlight New Clinical Data at ACAAI 2022 (GlobeNewswire)
Nov-03-22 04:30PM	DBV Technologies Reports Third Quarter Financial Results and Business Update (GlobeNewswire)
Oct-31-22 04:30PM	DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update (GlobeNewswire)
Oct-20-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2022 (GlobeNewswire)
Oct-03-22 04:30PM	DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors (GlobeNewswire)
Sep-21-22 05:45PM	DBV Technologies Provides Clinical Update on VITESSE Phase 3 Trial (GlobeNewswire) -7.24%
Sep-07-22 04:30PM	DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years (GlobeNewswire)
Sep-02-22 04:30PM	DBV Technologies to Present at Upcoming Investor Conferences (GlobeNewswire) +12.95% +7.80%
Aug-10-22 04:50PM	Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space (GlobeNewswire)
Aug-01-22 04:30PM	DBV Technologies Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-27-22 04:30PM	Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF (GlobeNewswire) +5.83%
Jul-20-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2022 (GlobeNewswire) +6.99%
Jun-28-22 06:15PM	DBV Technologies to Participate in Upcoming EAACI 2022 Congress (GlobeNewswire)
Jun-16-22 01:30AM	DBV Technologies to Present at the JMP Securities Life Sciences Conference in New York (GlobeNewswire)
Jun-09-22 02:55AM	DBV Technologies Announces Private Placement Financing of $194 Million (GlobeNewswire) +79.56%
Jun-07-22 04:30PM	DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers (GlobeNewswire) +18.30%
May-17-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2022 (GlobeNewswire) +5.74%
May-12-22 04:30PM	DBV Technologies Announces Results of Its 2022 Ordinary and Extraordinary General Meeting (GlobeNewswire)
May-04-22 07:30PM	DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM) (GlobeNewswire) +5.51%
May-02-22 05:00PM	DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq (GlobeNewswire) +7.36% -8.30%
04:00PM	DBV Technologies Reports Recent Business Developments and First Quarter 2022 Financial Results (GlobeNewswire)
Apr-25-22 07:30PM	Correction: DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments (GlobeNewswire)
04:30PM	DBV Technologies to Report First Quarter 2022 Financial Results and Recent Business Developments (GlobeNewswire)
Apr-21-22 04:30PM	Ordinary and Extraordinary General Meeting of May 12, 2022 (GlobeNewswire)
Apr-14-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2022 (GlobeNewswire)
Mar-14-22 04:30PM	DBV Technologies to Present at the Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-11-22 04:30PM	Monthly information regarding the total number of voting rights and total number of shares of the Company as of February 28, 2022 (GlobeNewswire)
Mar-09-22 04:30PM	DBV Technologies Announces Filing of 2021 Annual Report on Form 10-K and 2021 Universal Registration Document (GlobeNewswire) +5.34%
Mar-03-22 04:15PM	DBV Technologies Reports Full Year 2021 Financial Results and Recent Business Updates (GlobeNewswire) +34.62% -23.43%
Feb-24-22 04:30PM	DBV Technologies to Report Full Year 2021 Financial Results and Business Updates on March 3, 2022 (GlobeNewswire)
Feb-22-22 04:30PM	DBV Technologies to Participate in Upcoming AAAAI 2022 Congress (GlobeNewswire) -5.04%

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stephane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mohideen Pharis	Chief Medical Officer	Nov 25 '24	Sale	0.57	565	322	111,110	Nov 27 04:15 PM
Mohideen Pharis	Chief Medical Officer	Nov 22 '24	Sale	0.53	342	181	111,675	Nov 27 04:15 PM
Mohideen Pharis	Chief Medical Officer	Nov 21 '24	Sale	0.54	2,350	1,269	112,017	Nov 25 05:13 PM
Mohideen Pharis	Chief Medical Officer	Jul 29 '24	Sale	0.98	1,785	1,749	79,367	Jul 31 05:32 PM
Mohideen Pharis	Chief Medical Officer	May 24 '24	Sale	1.36	660	898	81,152	May 29 04:15 PM
Mohideen Pharis	Chief Medical Officer	May 22 '24	Sale	1.38	382	527	81,812	May 29 04:15 PM
Tasse Daniel	CHIEF EXECUTIVE OFFICER	Mar 08 '24	Buy	0.83	17,094	14,188	17,094	Mar 11 04:15 PM
Ndu Adora	Director	Feb 06 '24	Buy	0.89	1,825	1,624	1,825	Feb 08 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DBVT

DBV Technologies ADR

Upgrade your FINVIZ experience